Previous Article | Next Article 
Journal of Virology, October 2005, p. 12296-12303, Vol. 79, No. 19
0022-538X/05/$08.00+0 doi:10.1128/JVI.79.19.12296-12303.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
V3 Loop-Determined Coreceptor Preference Dictates the Dynamics of CD4+-T-Cell Loss in Simian-Human Immunodeficiency Virus-Infected Macaques
Siu-hong Ho,1
Lili Shek,1
Agegnehu Gettie,1
James Blanchard,2 and
Cecilia Cheng-Mayer1*
Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave., 7th Floor, New York, New York 10016,1
Tulane National Primate Research Center, Tulane University Medical Center, 18702 Three Rivers Road, Covington, Louisiana 704332
Received 27 May 2005/
Accepted 6 July 2005

ABSTRACT
We used experimental infection of rhesus macaques with envelope
gp120 V3 loop isogenic simian-human immunodeficiency virus (SHIV)
molecular clones to more clearly define the impact of human
immunodeficiency virus type 1 coreceptor usage in target cell
selectivity and the rates of CD4
+-T-cell depletion. Functional
assays demonstrate that substitution of the V3 loop of the pathogenic
CXCR4-tropic (X4) SHIV
SF33A2 molecular clone with the corresponding
sequences from the CCR5-tropic (R5) SHIV
SF162P3 isolate resulted
in a switch of coreceptor usage from CXCR4 to CCR5. The resultant
R5 clone, designated SHIV
SF33A2(V3), is replication competent
in vivo, infecting two of two macaques by intravenous inoculation
with peak viremia that is comparable to that seen in monkeys
infected with X4-SHIV
SF33A2. But while primary infection with
the X4 clone was accompanied by rapid and significant loss of
peripheral and secondary lymphoid CD4
+ T lymphocytes, infection
with R5-SHIV
SF33A2(V3) led to only a modest and transient loss.
However, substantial depletion of intestinal CD4
+ T cells was
observed in R5-SHIV
SF33A2(V3)-infected macaques. Moreover, naïve
T cells that expressed high levels of CXCR4 were rapidly depleted
in X4-SHIV
SF33A2-infected macaques, whereas R5-SHIV
SF33A2(V3) infection mainly affected memory T cells that expressed CCR5.
These findings in a unique isogenic system illustrate that coreceptor
usage is the principal determinant of tissue and target cell
specificity of the virus in vivo and dictates the dynamics of
CD4
+-T-cell depletion during SHIV infection.

INTRODUCTION
Since the discovery of the chemokine receptors CCR5 and CXCR4
as the major coreceptors (CoRs) for entry of human immunodeficiency
virus type 1 (HIV-1), mounting evidence indicates that coreceptor
expression and usage play crucial roles in viral transmission,
persistence, and pathogenesis (
28). Most HIV-1 strains transmitted
between humans use CCR5 as their coreceptor (R5 strains). With
progression to disease, variants that use CXCR4 (X4 viruses)
emerge in about 50% of infected individuals and are associated
with a more rapid rate of peripheral CD4
+-T-cell loss (
33).
We and others have used infection of nonhuman primates with
simian-human immunodeficiency virus (SHIV) expressing the envelopes
of R5 and X4 HIV-1 strains as a model system to study the impact
of coreceptor usage in HIV-1 infection and AIDS pathogenesis
(
4). In infection of rhesus macaques (RM) with R5 and X4 pathogenic
SHIVs, SHIV
SF162P3 and SHIV
SF33A, respectively, we previously
reported a slower rate of peripheral CD4
+-T-cell depletion in
R5-SHIV
SF162P3-infected RM that recapitulated the progression
of infection seen in humans (
13,
15). In contrast, infection
with pathogenic X4-SHIV
SF33A resulted in rapid and precipitous
decline in peripheral and lymphoid CD4
+ T cells, mirroring infection
with X4 isolates (
15,
16,
22). However, analysis of lamina propria
lymphocytes (LPLs) purified from jejunal tissues revealed that
R5-SHIV
SF162P3 caused severe depletion of mucosal CD4
+ T cells
within 2 weeks of infection, whereas the loss of mucosal CD4
+ T cells in X4-SHIV
SF33A-infected macaques was more gradual (
15).
Different tissue sites of replication and CD4
+-T-cell depletion
patterns in macaques infected with CXCR4- and CCR5-tropic viruses
have also been reported previously by others (
30,
31), leading
to the suggestion that target cell availability as influenced
by differential coreceptor expression and viral tropism as dictated
by coreceptor preference have profound consequences on clinical
disease. Nevertheless, the strains used in all these studies
were independent isolates, with variants that differed in genetic
sequences and, hence, in properties other than host cell tropism
which might have contributed to the differences seen in the
pathogenic sequela. For instance, a major (7 out of 10 clones)
and a minor (1 out of 10 clones) variant, as determined by V1
to V5
env sequences, that differed in their entry efficiency
and neutralization susceptibility were present in the R5-SHIV
SF162P3 isolate we used (
17). Furthermore, while both X4-SHIV
SF33A and
R5-SHIV
SF162P3 showed neutralization resistance, the X4 virus
appeared to be more fusogenic and cytopathic in vitro (
6,
7,
18). A confirmation that early targeting of different T-cell
populations and different tissues by X4 and R5 viruses is due
solely to the coreceptors used could greatly benefit from infection
of RM with variants that differ only in their coreceptor binding
site sequences.
For HIV-1, differential usage of coreceptor in vitro has been shown to depend on the charge and/or structure of the V3 loop of envelope gp120 (2, 8). Towards the objective of constructing isogenic SHIVs that differ only in coreceptor preference, the V3 loop of SHIVSF33A2, a molecular clone that displays the infection characteristics of the parental pathogenic X4-SHIVSF33A isolate in RM (14), was replaced with the corresponding region of the R5-SHIVSF162P3 isolate (18). The function and coreceptor choice of the resulting chimeric envelope glycoprotein were determined. Furthermore, infection of RM with virus expressing the chimeric V3 envelope, designated SHIVSF33A2(V3), was characterized and compared to infection with the X4 isogenic SHIVSF33A2 molecular clone.

MATERIALS AND METHODS
Cells.
Human osteosarcoma cells expressing CD4 and either CCR5 (HOS.CD4.CCR5)
or CXCR4 (HOS.CD4.CXCR4) were kind gifts from N. Landau (Salk
Institute, La Jolla, CA) and were maintained in Dulbecco's modified
Eagle's medium supplemented with 10% fetal bovine serum (FBS),
0.5 µg/ml of puromycin (Sigma-Aldrich, St. Louis, MO),
and penicillin-streptomycin. 293T cells used for transfection
were cultured in Dulbecco's modified Eagle's medium with 10%
FBS and penicillin-streptomycin. Human peripheral blood mononuclear
cells (PBMCs) were obtained by Ficoll-Hypaque gradient purification
followed by stimulation with 3 µg/ml of phytohemagglutinin
A (Sigma-Aldrich) in RPMI 1640 medium supplemented with 10%
FBS, 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin,
and 20 U/ml of interleukin-2 (Chiron Corp., Emeryville, CA).
Plasmid constructs and virus production.
PCR-based overlapping extension methodology was employed to replace the V3 loop of X4-SHIVSF33A2 env gp120 with that of R5-SHIVSF162P3. Briefly, a HincII-to-HindIII fragment of Env33A2 (6) (nucleotides 1249 to 2386 [GenBank accession number M38427]) was subcloned into pBlueScript KS II(+) vector to serve as the template for PCR amplifications. The inner amplification primers used were SH5 (5'-GGG GAA AGC ATT TTA TGC AAC AGG AGA CAT AAT AGG AGA TAT AAG ACA AGC ACA TTG TAA CAT TAG TAG AGC-3') and SH6 (5'-GCA TAA AAT GCT TTC CCC GGT CCT ATA GGT ATA CTT TTT CTT GTA TTG TTA TTG GGT CTT GTA C-3'), which encompassed the env gp120 V3 sequence of R5-SHIVSF162P3 (in italics, with overlapping regions underlined) flanked by the C2 and C3 sequences of X4-SHIVSF33A2. The outer primers used were T3 and T7. The amplified fragment was completely sequenced for verification, and an envelope expression vector containing the V3 chimeric env, Env33A2(V3), was constructed by subcloning the HincII-to-HindIII-amplified fragment back into Env33A2 (Fig. 1). The same fragment was ligated into the corresponding regions of SHIVSF33A2 3' DNA (14) to generate the 3' genome of the V3 isogenic clone SHIVSF33A2(V3). Env162P3 (18)-, Env33A2-, and Env33A2(V3)-pseudotyped luciferase reporter viruses were prepared by cotransfecting 293T cells with the NL4.3-Luc-ER vector and the corresponding Env expression plasmid using the DMRIE-C reagent (Invitrogen). Reporter viruses were harvested 72 h posttransfection and quantified for p24gag antigen content (Beckman Coulter, Fullerton, CA). SHIV was obtained by cotransfection of 293T cells with SIVmac239 5' and SHIVSF33A2 or SHIVSF33A2(V3) 3' hemigenomes followed by cocultivation with phytohemagglutinin A-stimulated PBMCs as previously described (23). Recovered viruses were amplified and propagated in human PBMCs, and culture supernatants were collected for viral p27gag antigen determination (Coulter Corporation, Miami, FL) and for assessment of the 50% tissue culture infectious dose in human PBMCs.
Entry and blocking assays.
A total of 5
x 10
3 HOS.CD4.CCR5 or HOS.CD4.CXCR4 cells were
seeded in 96-well plates 24 h before use. Cells were infected
with 5 ng p24 equivalent of the indicated pseudotyped viruses
in the presence of 2 µg/ml of polybrene followed by incubation
for 72 h at 37°C. At the end of the incubation period, cells
were harvested, lysed, and processed according to the manufacturer's
instructions (Promega, Madison, WI). Entry, as quantified by
luciferase activity, was measured with an MLX microtiter plate
luminometer (Dynex Technologies, Inc., Chantilly, VA). For the
blocking assay, 5
x 10
5 PBMCs were pretreated with various concentrations
of AOP-RANTES (a generous gift of Oliver Hartley, University
of Zurich) for 1 h before infection. Percent blocking was calculated
by the amount of entry in the presence of AOP-RANTES relative
to that in the absence of AOP-RANTES.
Animal infections.
All infections were carried out in adult RM (Macaca mulatta) individually housed at the Tulane National Primate Research Center in compliance with the Guide for the Care and use of Laboratory Animals (28a). Animals were confirmed to be serologically negative for simian type D retrovirus, simian immunodeficiency virus (SIV), and simian T-cell lymphotrophic virus prior to infection. Whole blood lymphocytes were sampled at designated time intervals. Plasma viremia was quantified by branched DNA analysis (Bayer Diagnotics, Emeryville, CA), and absolute CD4+ and CD8+ cell counts were monitored by TruCount (BD Biosciences, Palo Alto, CA). Biopsy samples were obtained by surgery at 2 and 8 weeks postinfection (wpi) for the SHIVSF33A2(V3)-infected animals and at 2 and 9 wpi for the SHIVSF33A2-inoculated animals. The percentages of CD4+ T cells in the biopsy samples were analyzed by flow cytometry (FACScalibur) using CD3-fluorescein isothiocyanate (FITC), CD4-phycoerythrin (PE), and CD8-peridinin chlorophyll protein antibodies. Further phenotyping of peripheral and lymphoid CD4+ T cells was performed by using CD28-allophycocyanin, CD95-PE or -FITC, CCR5-PE, and CXCR4-PE. Except for CD3-FITC (BioSource, Camarillo, CA), all antibodies were obtained from BD Biosciences.

RESULTS
The V3 loop of X4-SHIVSF33A2 dictates CoR usage.
The 35-amino-acid V3 domains of the X4-SHIV
SF33A2 molecular
clone and the R5-SHIV
SF162P3 isolate differ in 10 amino acids
(Fig.
1), with the overall charge of this region being +7 for
SHIV
SF33A2 and +5 for SHIV
SF162P3, values that are consistent
with those reported previously for other X4 and R5 HIV-1 strains
(
10). In single-round infectivity assays, we found that contrary
to Env33A2, the chimeric V3 envelope Env33A2(V3) was not able
to mediate entry into HOS.CD4 cells expressing CXCR4. Instead,
Env33A2(V3), similar to Env162P3, used CCR5 as the CoR (Fig.
2A). To confirm the coreceptor usage of Env33A2(V3), blocking
of entry into human PBMCs with AOP-RANTES, an amino terminus-modified
form of the CCR5 natural ligand RANTES (
36), was assessed. Results
showed that entry of virus expressing Env33A2(V3) was efficiently
blocked by AOP-RANTES in a dose-dependent manner, while virus
expressing Env33A2 was not affected, even at a concentration
of 250 nM (Fig.
2B). In fact, a slight increase in Env33A2-mediated
infection in the presence of high concentrations of AOP-RANTES
(>50 nM) was observed, consistent with reports of stimulation
of X4 virus replication by CC chemokines (
9,
19). Taken together,
the data showed that Env33A2(V3) is functional and that the
substitution of the V3 loop of Env33A2 with that of Env162P3
resulted in a switch in coreceptor usage from CXCR4 to CCR5.
SHIVSF33A2(V3) is replication competent in RM.
Env33A2(V3) was then used to replace the corresponding region
of X4-SHIV
SF33A2 to construct the chimeric virus SHIV
SF33A2(V3).
The two clones differ only in the V3 loop, with an overall identity
of 99.88%. Two macaques each were inoculated intravenously with
10
3 50% tissue culture infectious doses of R5-SHIV
SF33A2(V3) (macaques BT35 and CF17) or X4-SHIV
SF33A2 (macaques CA05 and
CA06). All four animals were infected, with peak viremia of
10
6 to 10
8 RNA copies/ml plasma at 2 to 3 wpi and with kinetics
of virus replication slightly faster in the X4-SHIV
SF33A2-infected
macaques than in the R5-SHIV
SF33A2(V3)-infected macaques (Fig.
3A and B). Replication of both viruses declined thereafter,
with a postpeak viral load of 10
2 to 10
3 RNA copies/ml plasma
at 20 wpi.
The dynamics of CD4+-T-cell loss differ in R5-SHIVSF33A2(V3)- and X4-SHIVSF33A2-infected macaques.
We next examined the impact of X4 and R5 clone infection on
the CD4
+-T-cell compartment. A drop in peripheral CD4
+ T cells,
a feature that is characteristic of infection with the pathogenic
isolate R5-SHIV
SF162P3 and with SIV, was observed in both R5-SHIV
SF33A2(V3)-infected
animals during peak viremia (2 to 3 wpi). The levels of circulating
CD4
+ T lymphocytes fluctuated thereafter but rebounded close
to preinfection values by 8 wpi (Fig.
3B). In contrast, X4-SHIV
SF33A2 infection led to a rapid and more sustained loss of peripheral
CD4
+ T cells (Fig.
3A).
To further examine the impact of CoR usage on the dynamics of the CD4+-T-cell compartment, the percentages of CD4+ T cells in various lymphoid and nonlymphoid tissues during peak (2 to 3 wpi) and postpeak (8 to 9 wpi) infection were analyzed (Fig. 4). No significant loss in CD4+ T cells was noted in the draining and peripheral lymph nodes (LNs) of the two R5-SHIVSF33A2(V3)-infected animals during the peak or postpeak infection period (Fig. 4B). Despite a viral load that is comparable to that of the R5-SHIVSF33A2(V3)-infected animals, however, a 30 to 50% loss of CD4+ T cells was found in all lymphoid tissues of CA05 examined at 9 wpi (Fig. 4A). In CA06, the X4-SHIVSF33A2-infected animal with a log higher peak viremia, massive depletion of CD4+ T cells was seen in both the draining and systemic LNs within 2 weeks of infection, with some degree of restoration noted in these secondary LNs by 9 wpi.
Contrary to what was observed in the secondary lymphoid compartments,
a 60% and 55% drop in CD4
+ T cells in the bone marrow (BM) and
mucosal tissues such as the lamina propria of the gut (LPL),
respectively, in CF17 was present at 8 wpi (Fig.
4B). A similar
degree of postpeak CD4
+-T-cell loss was also noted in the BM
and LPL in the other R5-SHIV
SF33A2(V3)-infected monkey, BT35.
For X4-SHIV
SF33A2 infection, a decrease in BM CD4
+ T cells (25%)
was seen in CA05 at 2 wpi, but dramatic depletion was already
present in CA06. While the gut remained relatively intact in
both X4 clone-infected macaques at 2 wpi, substantial CD4
+-T-cell
depletion (60%) was detected in CA06 by 9 wpi (Fig.
4A), while
CA05 displayed a more modest loss (25%). The targeting of BM
by the X4 and R5 isogenic SHIV molecular clones is in agreement
with reports that CD34
+ progenitor cells could be infected by
HIV-1 variants with different phenotypes (
34,
41). Furthermore,
although the dynamics of CD4
+-T-cell loss among the two X4-SHIV
SF33A2-infected
macaques varies due to a difference in viral load, the data
show that by switching the coreceptor usage of this clone virus
through replacement of its V3 loop, the site of early virus
replication changes. While the X4 clone preferentially targets
and depletes cells in peripheral blood and secondary LNs within
the first few weeks of infection, the R5 clone targets mucosal
tissue sites. The preferential depletion of CD4
+ T cells in
the gut and not the LNs of the R5 clone-infected animals during
primary infection is consistent with observations made in HIV-1-infected
humans (
5,
11,
27), SIV-infected macaques (
21,
25,
26,
37,
39),
and animals infected with the pathogenic R5-SHIV
SF162P3 isolate
(
15).
T-cell-subset distribution and CoR expression varied in lymphoid and mucosal tissues of RM.
CXCR4 and CCR5 are differentially expressed on naïve and memory CD4+ T cells, the two major T-cell subpopulations that can be distinguished in macaque cells by surface staining for the CD28 and CD95 antigens (32). To determine whether the differential compartmentalization of the X4 and R5 clones during primary infection is influenced by the availability and susceptibility of their target cells, the frequency of the two T-cell subsets in various lymphoid and mucosal tissues and CoR expression on their surface were determined (Fig. 5). Consistent with previous reports (1, 3, 20, 35, 38, 40), naïve (CD95low CD28high) CD4+ T lymphocytes were found in abundance in the periphery and LNs but were rare in the gut. More than 95% of cells in this latter compartment were memory cells (CD95high CD28high or CD95high CD28low) (Fig. 5A). Virtually all the naïve cells were positive for CXCR4 and negative for CCR5 (Fig. 5B), while cells of the memory phenotype expressed both receptors, with higher CCR5 expression on memory cells in the gut than in the periphery and secondary lymphoid compartments (Fig. 5C). Within the macaque host, therefore, there is greater representation of CXCR4-positive cells in peripheral blood and LNs, while the majority of CCR5-expressing cells reside in mucosal effector sites. This, then, explains the early preferential targeting of the X4 clone to the periphery and LN compartments and the R5 clone to the gut-associated lymphoid tissue since the greatest number of their respective target cells reside in these compartments.
Differential target cell selectivity in R5-SHIVSF33A2(V3)- and X4-SHIVSF33A2-infected macaques.
To further establish CoR specificity of the two clones in vivo
and to assess the impact of CoR preference on target cell selectivity,
changes in the phenotype (Fig.
6) as well as chemokine receptor
expression (Fig.
7) in circulating and lymphoid CD4
+ T cells
were determined. As anticipated, the X4 clone selectively targeted
and depleted naïve CD4
+ T cells in peripheral blood. The
percentage of this T-cell subpopulation dropped from a baseline
value of 63.8% to 42% within 2 to 4 weeks of infection in CA05
(Fig.
6A) and further declined by 6 wpi (Fig.
6B). A more drastic
loss of naïve T cells, from 57.4% to 1.5% within 2 weeks
of infection, was seen in CA06, the monkey with the higher peak
viremia (Fig.
6A). By 6 wpi, >99.9% of circulating CD4
+ T
cells in CA06 were cells of the memory phenotype (Fig.
6B).
Similar preferential early targeting of naïve T cells was
also seen in the LNs, where loss of this T-cell subset accounted
for the total drop in percentage of CD4
+ T cells (Fig.
6C).
For animals infected with the R5-SHIV
SF33A2(V3) clone, a rather
modest (

15%) but specific loss of memory cells was observed
in CF17 at 2 to 4 wpi (Fig.
6A), and this further decreased
at 5 wpi before rebounding close to preinfection values by 6
wpi (Fig.
6B). In BT35, an increase in the memory T-cell subset,
similar to that reported for SIV infection (
25), was seen at
1 wpi, and this was followed by a gradual decline.
When changes in chemokine receptor expression on circulating
CD4
+ T lymphocytes were examined, results showed that naïve
cells expressing high levels of CXCR4 were selectively eliminated
in early X4-SHIV
SF33A2 infection, followed or accompanied by
depletion of CXCR4
+ memory cells (Fig.
7A). The difference in
the tempo of depletion of the two CXCR4
+-T-cell subpopulations
was more evident in CA06, where a complete loss of naïve
CXCR4
+ cells compared to a 40% drop in CXCR4
+ memory cells was
present at 3 wpi. In contrast, a transient drop in CCR5
+ memory
T lymphocytes was seen in both R5-SHIV
SF33A2(V3)-infected macaques
at 3 wpi, and this was accompanied by a corresponding increase
in the percentage of CXCR4
+ memory T cells (Fig.
7B). By 5 wpi,
however, a rebound in the percentage of CCR5
+ memory cells was
noted. The selective destruction of CXCR4
+ lymphocytes by the
X4 clone and CCR5
+ lymphocytes by the R5 clone further demonstrates
their CoR specificity in vivo and shows that in addition to
the extent of virus replication, the dynamics of CD4
+-T-cell
loss are influenced by the CoR usage of the inoculating virus,
the level of CoR expression on target cells, and the representation
of these cells in the various tissue compartments.

DISCUSSION
The use of SHIV isogenic clones that differ only in their CoR
binding sequences for infection of nonhuman primates provides
an ideally suited model to study the impact of HIV-1 coreceptor
usage on the composition and dynamics of the CD4
+-T-cell compartment.
We report here the generation and characterization of such viruses.
We show that the substitution of the V3 loop of the X4-SHIV
SF33A2 molecular clone with the corresponding sequences of the R5-SHIV
SF162P3 isolate alone was sufficient to alter its coreceptor preference
in vitro and its replication characteristics in vivo. Differences
in the sites of early virus replication as well as the rates
of CD4
+-T cell-loss in the periphery, LNs, and mucosal tissue
compartments were seen in RM infected with the X4 compared to
the R5 isogenic SHIV molecular clones. Infection with X4-SHIV
SF33A2 resulted in a rapid drop, massively in the case of CA06, in
CD4
+-T-cell numbers in peripheral blood and secondary LNs during
the period of peak virus production (Fig.
3 and
4). This loss
of CD4
+ T cells in the peripheral tissues preceded depletion
of CD4
+ T cells in the intestinal mucosa of CA06, the X4-SHIV
SF33A2-infected
macaque with the highest viral burden. In contrast, loss of
CD4
+ T cells in the blood of both R5-SHIV
SF33A2(V3)-infected
macaques was modest and transient, with little or no depletion
seen in the secondary lymph nodes during primary infection.
However, lower percentages of CD4
+ T cells were seen in the
gut-associated lymphoid tissue, consistent with preferential
depletion in mucosal effector sites by the R5 clone. These observations
of differential sites of early virus replication in animals
infected with the X4 and R5 isogenic clones are consistent with
previous findings in animals infected with the pathogenic X4-SHIV
SF33A and R5-SHIV
SF162P3 isolates (
15) and demonstrate that coreceptor
utilization, and not other undetermined strain-related differences,
is the major determinant for this difference.
We showed not only differential early targeting of various tissue compartments in X4 and R5 clone-infected macaques but also preferential depletion of particular CD4+-T-cell subsets within these compartments. Naïve T cells were dramatically depleted in X4-SHIVSF33A2-infected macaques, whereas the memory T cells were targeted by R5-SHIVSF33A2(V3) (Fig. 6 and 7). These findings of differences in tissue and T-cell targeting by X4 and R5 viruses can, to a large extent, be explained by differential expression of their cognate receptors on the two major CD4+-T-cell subsets and the relative tissue distribution of these cell populations in vivo. CCR5 expression is largely restricted to memory T cells that are infrequent in peripheral blood and LNs but prevalent in tissue effector sites such as intestinal lamina propria (Fig. 5). Accordingly, CD4+-T-cell loss occurs predominantly in the gut of R5-SHIVSF33A2(V3)-infected macaques, with only modest depletion seen in peripheral blood (Fig. 3) and no depletion seen in the secondary lymphoid tissue compartments (Fig. 4). In contrast, CXCR4 is expressed on memory as well as naïve CD4+ T cells in peripheral blood and all lymphoid tissues examined (Fig. 5). In this regard, the observation that the loss of CD4+ T cells in the peripheral tissues was followed by elimination of CD4+ T cells in the intestinal mucosa of CA06 indicates that there is no absolute restriction in the sites of CD4+-T-cell depletion induced by SHIV infection but that the rate and extent of T-cell loss in these various tissue compartments are influenced by the total number of susceptible target cells that are available within these sites. Conceivably, the faster kinetics of replication seen for the X4 isogenic clone are due to the larger pool of susceptible target cells available for this virus (Fig. 3A and 5). Furthermore, the greater frequency and abundance of CXCR4 expression on naïve cells compared to memory cells can explain the early targeting of this T-cell subset by X4-SHIVSF33A2. The effects of infection by CXCR4- and CCR5-using viruses on naïve and memory CD4 subsets have recently been described using X4-SHIV and SIV (29-31). Our use of an isogenic system, showing early depletion of CXCR4+ naïve cells by the X4-SHIVSF33A2 molecular clone and CCR5+ memory cells by the R5-SHIVSF33A2(V3) clone (Fig. 7), confirms and extends findings in those other reports, demonstrating that coreceptor preference is the principal basis of this selectivity.
In a prior study, one of two macaques inoculated intravenously with a cell-free X4-SHIVSF33A2 molecular clone suffered precipitous peripheral CD4+-T-cell loss and progression to simian AIDS within 30 wpi, while the other displayed a less severe but sustained depletion of CD4+ T cells and controlled its infection (14). The variability in the level of viremia and kinetics and extent of cell destruction seen in these and the present two macaques infected with the X4-SHIVSF33A2 molecular clone contrasts with the patterns observed in animals infected with the uncloned X4-SHIVSF33A strain, suggesting that the clonal virus is less pathogenic than the viral isolate. But the possibility of individual host variability cannot be excluded. Additional studies in a larger group of animals are required to address this. Despite these variations, however, the data show that the pattern of CD4+-T-cell loss induced by X4-SHIVSF33A2 clone infection is dramatically altered through modifications of its V3 loop. Furthermore, the availability of these X4 and R5 isogenic SHIV molecular clones for infection of macaques is expected to enhance our understanding of the role of tropism in transmission, persistence, and pathogenesis of HIV-1 infection. For example, coinfection of RM with these viruses should allow us to determine whether cell tropism alone dictates the R5 dominance we observed in macaques dually infected with the pathogenic isolates X4-SHIVSF33A and R5-SHIVSF162P3 (12). Additionally, since the sites of replication and immune cells targeted by the clones differ, questions of interest will be whether the type and/or extent of selective immune pressures exerted by the shared host on the two viruses will differ as well. An examination of sequence changes in the envelope and/or other genomic regions of viruses recovered from isogenic X4- and R5-SHIV-infected macaques over time, coupled with antiviral immune measurements, may provide critical insights into these questions. Last, although coreceptor switch has rarely been reported in SIV-infected macaques (24, 31), infection with the R5-SHIVSF33A2(V3) clone, a virus generated on the backbone of an X4 clone with only 10 amino acid changes in the V3 loop, may provide a unique opportunity to investigate whether reversion to an X4 phenotype can occur in infection of RM.
In summary, although the number of animals used is limited, this proof-of-concept study using an isogenic system clearly shows that the course of infection with the X4-SHIVSF33A2 molecular clone is markedly altered by changing its coreceptor choice through replacement of its V3 loop sequences with those of an R5 strain. Coreceptor targeting of specific CD4+-T-cell subpopulations coupled with the susceptibility and distribution of the target cells contribute to the differing rates and sites of CD4+-T-cell depletion seen in X4-SHIVSF33A2- and R5-SHIVSF33A2(V3)-infected macaques. Further studies with these two clones in larger, more systematic studies are expected to provide important information on the role of tropism in HIV-1 infection and disease induction.

ACKNOWLEDGMENTS
We thank Lisa Chakrabarti and Viviana Simon for critical comments
and Peter Lopez for help with fluorescence-activated cell sorter
analyses.
This research was supported by grants from the U.S. National Institutes of Health (AI46980, AI41945, and CA72822).

FOOTNOTES
* Corresponding author. Mailing address: Rockefeller University, Aaron Diamond AIDS Research Center, 455 First Ave., 7th Floor, New York, NY 10016. Phone: (212) 448-5080. Fax: (212) 448-5158. E-mail:
cmayer{at}adarc.org.


REFERENCES
1 - Anton, P. A., J. Elliott, M. A. Poles, I. M. McGowan, J. Matud, L. E. Hultin, K. Grovit-Ferbas, C. R. Mackay, I. S. Y. Chen, and J. V. Giorgi. 2000. Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS 14:1761-1765.[CrossRef][Medline]
2 - Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700.[CrossRef][Medline]
3 - Bleul, C., L. Wu, J. A. Hoxie, T. A. Springer, and C. R. Mackay. 1997. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA 94:1925-1930.[Abstract/Free Full Text]
4 - Bogers, W. M., C. Cheng-Mayer, and R. C. Montelaro. 2000. Developments in preclinical AIDS vaccine efficacy models. AIDS 14(Suppl. 3):S141-S151.
5 - Brenchley, J. M., T. W. Schacker, L. E. Ruff, D. A. Price, J. H. Taylor, G. J. Beilman, P. L. Nguyen, A. Khoruts, M. Larson, A. T. Haase, and D. C. Douek. 2004. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200:749-759.[Abstract/Free Full Text]
6 - Chakrabarti, L. A., T. Ivanovic, and C. Cheng-Mayer. 2002. Properties of the surface envelope glycoprotein associated with virulence of simian-human immunodeficiency virus SHIVSF33A molecular clones. J. Virol. 76:1588-1599.[Abstract/Free Full Text]
7 - Cheng-Mayer, C., A. Brown, J. Harouse, P. A. Luciw, and A. J. Mayer. 1999. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. J. Virol. 73:5294-5300.[Abstract/Free Full Text]
8 - Cocchi, F., A. L. DeVico, A. Garzino-Demo, A. Cara, R. C. Gallo, and P. Lusso. 1996. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat. Med. 2:1244-1247.[CrossRef][Medline]
9 - Dolei, A., A. Biolchini, C. Serra, S. Curreli, E. Gomes, and F. Dianzani. 1998. Increased replication of T-cell-tropic HIV strains and CXC-chemokine receptor-4 induction in T cells treated with macrophage inflammatory protein (MIP)-1alpha, MIP-1beta and RANTES beta-chemokines. AIDS 12:183-190.[CrossRef][Medline]
10 - Fouchier, R. M., M. Groenink, A. Kootstra, M. Tersmette, H. G. Huisman, F. Miedema, and H. Schuitemaker. 1992. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J. Virol. 66:3183-3187.[Abstract/Free Full Text]
11 - Guadalupe, M., E. Reay, S. Sankaran, T. Prindiville, J. Flamm, A. McNeil, and S. Dandekar. 2003. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J. Virol. 77:11708-11717.[Abstract/Free Full Text]
12 - Harouse, J. M., C. Buckner, A. Gettie, R. Fuller, R. Bohm, J. Blanchard, and C. Cheng-Mayer. 2003. CD8+ T cell-mediated CXC chemokine receptor 4-simian/human immunodeficiency virus suppression in dually infected rhesus macaques. Proc. Natl. Acad. Sci. USA 100:10977-10982.[Abstract/Free Full Text]
13 - Harouse, J. M., A. Gettie, T. Eshetu, R. C. Tan, R. Bohm, J. Blanchard, G. Baskin, and C. Cheng-Mayer. 2001. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIVSF162P3. J. Virol. 75:1990-1995.[Abstract/Free Full Text]
14 - Harouse, J. M., A. Gettie, R. C. Tan, T. Eshetu, M. Ratterree, J. Blanchard, and C. Cheng-Mayer. 2001. Pathogenic determinants of the mucosally transmissible CXCR4-specific SHIVSF33A2 map to env region. J. Acquir. Immune Defic. Syndr. 27:222-228.
15 - Harouse, J. M., A. Gettie, R. C. H. Tan, J. Blanchard, and C. Cheng-Mayer. 1999. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284:816-819.[Abstract/Free Full Text]
16 - Harouse, J. M., R. C. Tan, A. Gettie, P. Dailey, P. A. Marx, P. A. Luciw, and C. Cheng-Mayer. 1998. Mucosal transmission of pathogenic CXCR4-utilizing SHIVSF33A variants in rhesus macaques. Virology 248:95-107.[CrossRef][Medline]
17 - Hsu, M., C. Buckner, J. Harouse, A. Gettie, J. Blanchard, J. E. Robinson, and C. Cheng-Mayer. 2003. Antigenic variations in the CD4 induced sites of the CCR5-tropic, pathogenic SHIVSF162P3 gp120 variants. J. Med. Primatol. 32:211-217.[CrossRef][Medline]
18 - Hsu, M., J. M. Harouse, A. Gettie, C. Buckner, J. Blanchard, and C. Cheng-Mayer. 2003. Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIVSF162P3 maps to envelope gp120. J. Virol. 77:989-998.
19 - Kinter, A., A. Catanzaro, J. Monaco, M. Ruiz, J. Justement, S. Moir, J. Arthos, A. Oliva, L. Ehler, S. Mizell, R. Jackson, M. Ostrowski, J. Hoxie, R. Offord, and A. S. Fauci. 1998. CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: role of signal transduction. Proc. Natl. Acad. Sci. USA 95:11880-11885.[Abstract/Free Full Text]
20 - Kunkel, E. J., J. Boisvert, K. Murphy, M. A. Vierra, M. C. Genovese, A. J. Wardlaw, H. B. Greenberg, M. R. Hodge, L. Wu, E. C. Butcher, and J. J. Campbell. 2002. Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. Am. J. Pathol. 160:347-355.[Abstract/Free Full Text]
21 - Li, Q., L. Duan, J. D. Estes, Z. M. Ma, T. Rourke, Y. Wang, C. Reilly, J. Carlis, C. J. Miller, and A. T. Haase. 2005. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 434:1148-1152.[Medline]
22 - Luciw, P., C. Mandell, S. Himathongkham, J. Li, T. Low, K. Schmidt, K. Shaw, and C. Cheng-Mayer. 1999. Fatal immunopathogenesis by SIV/HIV-1 (SHIV) containing a variant form of the HIV-1SF33 env gene in juvenile and newborn rhesus macaques. Virology 263:112-127.[CrossRef][Medline]
23 - Luciw, P. A., E. Pratt-Lowe, K. E. S. Shaw, J. A. Levy, and C. Cheng-Mayer. 1995. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc. Natl. Acad. Sci. USA 92:7490-7494.[Abstract/Free Full Text]
24 - Marx, P. A., and Z. Chen. 1998. The function of simian chemokine receptors in the replication of SIV. Semin. Immunol. 10:215-223.[CrossRef][Medline]
25 - Mattapallil, J. J., D. C. Douek, B. Hill, Y. Nishimura, M. Martin, and M. Roederer. 2005. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434:1093-1097.[CrossRef][Medline]
26 - Mattapallil, J. J., Z. Smit-McBride, M. McChesney, and S. Dandekar. 1998. Intestinal intraepithelial lymphocytes are primed for gamma interferon and MIP-1ß expression and display antiviral cytotoxic activity despite severe CD4+ T-cell depletion in primary SIV infection. J. Virol. 72:6421-6429.[Abstract/Free Full Text]
27 - Mehandru, S., M. A. Poles, K. Tenner-Racz, A. Horowitz, A. Hurley, C. Hogan, D. Boden, P. Racz, and M. Markowitz. 2004. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200:761-770.[Abstract/Free Full Text]
28 - Moore, J. P., S. G. Kitchen, P. Pugach, and J. A. Zack. 2004. The CCR5 and CXCR4 coreceptorscentral to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retrovir. 20:111-126.[CrossRef][Medline]
28 - National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
29 - Nishimura, Y., C. R. Brown, J. J. Mattapallil, T. Igarashi, A. Buckler-White, B. A. Lafont, V. M. Hirsch, M. Roederer, and M. A. Martin. 2005. Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques. Proc. Natl. Acad. Sci. USA 102:8000-8005.[Abstract/Free Full Text]
30 - Nishimura, Y., T. Igarashi, O. K. Donau, A. Buckler-White, C. Buckler, B. A. Lafont, R. M. Goeken, S. Goldstein, V. M. Hirsch, and M. A. Martin. 2004. Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc. Natl. Acad. Sci. USA 101:12324-12329.[Abstract/Free Full Text]
31 - Picker, L. J., S. I. Hagen, R. Lum, E. F. Reed-Inderbitzin, L. M. Daly, A. W. Sylwester, J. M. Walker, D. C. Siess, M. Piatak, Jr., C. Wang, D. B. Allison, V. C. Maino, J. D. Lifson, T. Kodama, and M. K. Axthelm. 2004. Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive simian immunodeficiency virus infection. J. Exp. Med. 200:1299-1314.[Abstract/Free Full Text]
32 - Pitcher, C. J., S. I. Hagen, J. M. Walker, R. Lum, B. L. Mitchell, V. C. Maino, M. K. Axthelm, and L. J. Picker. 2002. Development and homeostasis of T cell memory in rhesus macaque. J. Immunol. 168:29-43.[Abstract/Free Full Text]
33 - Rowland-Jones, S. L. 2003. Timeline: AIDS pathogenesis: what have two decades of HIV research taught us? Nat. Rev. Immunol. 3:343-348.[CrossRef][Medline]
34 - Ruiz, M. E., C. Cicala, J. Arthos, A. Kinter, A. T. Catanzaro, J. Adelsberger, K. L. Holmes, O. J. Cohen, and A. S. Fauci. 1998. Peripheral blood-derived CD34+ progenitor cells: CXC chemokine receptor 4 and CC chemokine receptor 5 expression and infection by HIV. J. Immunol. 161:4169-4176.[Abstract/Free Full Text]
35 - Sallusto, F., D. Lenig, C. R. Mackay, and A. Lanzavecchia. 1998. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med. 187:875-883.[Abstract/Free Full Text]
36 - Simmons, G., P. R. Clapham, L. Picard, R. E. Offord, M. M. Rosenkilde, T. W. Schwartz, R. Buser, T. N. C. Wells, and A. E. Proudfoot. 1997. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276:276-279.[Abstract/Free Full Text]
37 - Smit-McBride, Z., J. J. Mattapallil, M. McChesney, D. Ferrick, and S. Dandekar. 1998. Gastrointestinal T lymphocytes retain high potential for cytokine responses but have severe CD4+ T-cell depletion at all stages of simian immunodeficiency virus infection compared to peripheral lymphocytes. J. Virol. 72:6646-6656.[Abstract/Free Full Text]
38 - Vajdy, M., R. Veazey, I. Tham, C. deBakker, S. Westmoreland, M. Neutra, and A. Lackner. 2001. Early immunologic events in mucosal and systemic lymphoid tissues after intrarectal inoculation with simian immunodeficiency virus. J. Infect. Dis. 184:1007-1014.[CrossRef][Medline]
39 - Veazey, R. S., M. DeMaria, L. V. Chalifoux, D. E. Shvetz, D. R. Pauley, H. L. Knight, M. Rosenzweig, R. P. Johnson, R. C. Desrosiers, and A. A. Lackner. 1998. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280:427-431.[Abstract/Free Full Text]
40 - Veazey, R. S., K. G. Mansfield, I. C. Tham, A. C. Carville, D. E. Shvetz, A. E. Forand, and A. A. Lackner. 2000. Dynamics of CCR5 expression by CD4+ T cells in lymphoid tissues during simian immunodeficiency virus infection. J. Virol. 74:11001-11007.[Abstract/Free Full Text]
41 - Weiser, B., H. Burger, P. Campbell, S. Donelan, and J. Mladenovic. 1996. HIV type 1 RNA expression in bone marrows of patients with a spectrum of disease. AIDS Res. Hum. Retrovir. 12:1551-1558.[Medline]
Journal of Virology, October 2005, p. 12296-12303, Vol. 79, No. 19
0022-538X/05/$08.00+0 doi:10.1128/JVI.79.19.12296-12303.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Tasca, S., Ho, S.-H., Cheng-Mayer, C.
(2008). R5X4 Viruses Are Evolutionary, Functional, and Antigenic Intermediates in the Pathway of a Simian-Human Immunodeficiency Virus Coreceptor Switch. J. Virol.
82: 7089-7099
[Abstract]
[Full Text]
-
Ho, S.-h., Trunova, N., Gettie, A., Blanchard, J., Cheng-Mayer, C.
(2008). Different Mutational Pathways to CXCR4 Coreceptor Switch of CCR5-Using Simian-Human Immunodeficiency Virus. J. Virol.
82: 5653-5656
[Abstract]
[Full Text]
-
Ho, S.-h., Tasca, S., Shek, L., Li, A., Gettie, A., Blanchard, J., Boden, D., Cheng-Mayer, C.
(2007). Coreceptor Switch in R5-Tropic Simian/Human Immunodeficiency Virus-Infected Macaques. J. Virol.
81: 8621-8633
[Abstract]
[Full Text]